Stemson Announces Technological Breakthrough In New Hair Growth
February 6, 2024
Stemson Therapeutics today announced a major technological advance that clears the path for its proprietary hair rejuvenation solution to advance toward human clinical trials. Stemson is developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles and has successfully created human hair follicles in humanized mice using engineered follicular units (EFUs). The EFUs are designed to provide an unlimited source of hair follicle replacements capable of treating a range of hair loss indications, including Androgenetic Alopecia, Scarring Alopecia, and Chemo-Induced Alopecia.